Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation

Bone Marrow Transplantation volume 35, pages 1065–1069 (2005)Cite this article

Summary:

Patients undergoing haemopoietic stem cell transplants (HSCT) are at high risk of varicella zoster virus (VZV) reactivation, with a significant incidence of dissemination. This study reports a retrospective analysis of 247 allogeneic HSCT recipients receiving anti-viral prophylaxis with low-dose oral aciclovir 400 mg/day, administered until immunosuppression was discontinued and the CD4+ cell count exceeded 200/mm3. Viral reactivation was successfully suppressed by aciclovir prophylaxis, with only one case of breakthrough infection. The cumulative incidence of zoster infection at 1 year post transplant was 2% and at 5 years 34%. In all, 64 patients discontinued prophylaxis. Zoster developed in 26 of these, giving a cumulative incidence of infection at 1 year after stopping aciclovir of 39% and at 3 years 44%. Infection occurred in a localised dermatomal distribution in 93% of cases. This supports previous findings that aciclovir prophylaxis prevents early VZV reactivation, although the long-term incidence is not affected as infection occurs once prophylaxis is discontinued. Such infection, however, is mild and localised. This study does not support the idea that use of such low-dose aciclovir regimens reduces the zoster incidence by permitting subclinical reactivation during prophylaxis, and therefore the re-establishment of protective anti-viral immunity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Arvin AM . Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 219–230.

    Article  CAS  Google Scholar 

  2. Levin MJ, Hayward AR . The varicella vaccine. Prevention of herpes zoster. Infect Dis Clin N Am 1996; 10: 657–675.

    Article  CAS  Google Scholar 

  3. Moffat JF, Stein MD, Kaneshima H, Arvin AM . Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol 1995; 69: 5236–5242.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Koc Y, Miller KB, Schenkein DP et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000; 6: 44–49.

    Article  CAS  Google Scholar 

  5. Locksley RM, Flournoy N, Sullivan KM, Meyers JD . Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152: 1172–1181.

    Article  CAS  Google Scholar 

  6. Han CS, Miller W, Haake R, Weisdorf D . Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13: 277–283.

    CAS  Google Scholar 

  7. Atkinson K, Meyers JD, Storb R et al. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980; 29: 47–50.

    Article  CAS  Google Scholar 

  8. Chapman RS, Cross KW, Fleming DM . The incidence of shingles and its implications for vaccination policy. Vaccine 2003; 21: 2541–2547.

    Article  Google Scholar 

  9. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419–2425.

    CAS  Google Scholar 

  10. Ljungman P, Wilczek H, Gahrton G et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1986; 1: 185–192.

    CAS  Google Scholar 

  11. Selby PJ, Powles RL, Easton D et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 1989; 59: 434–438.

    Article  CAS  Google Scholar 

  12. Steer CB, Szer J, Sasadeusz J et al. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000; 25: 657–664.

    Article  CAS  Google Scholar 

  13. Kanda Y, Mineishi S, Saito T et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 689–692.

    Article  CAS  Google Scholar 

  14. Wilson A, Sharp M, Koropchak CM et al. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992; 165: 119–126.

    Article  CAS  Google Scholar 

  15. Zhang Y, Cosyns M, Levin MJ, Hayward AR . Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures. Clin Exp Immunol 1994; 98: 128–133.

    Article  CAS  Google Scholar 

  16. Redman RL, Nader S, Zerboni L et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176: 578–585.

    Article  CAS  Google Scholar 

  17. Hata A, Asanuma H, Rinki M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347: 26–34.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, University College London Hospitals, London, UK

    K J Thomson, D P Hart, L Banerjee, K S Peggs & S Mackinnon

  2. Department of Virology, University College London, London, UK

    K N Ward

Authors
  1. K J Thomson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D P Hart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Banerjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K N Ward
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K S Peggs
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Mackinnon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K J Thomson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomson, K., Hart, D., Banerjee, L. et al. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 35, 1065–1069 (2005). https://doi.org/10.1038/sj.bmt.1704959

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704959

Keywords

This article is cited by

Search

Advanced search

Quick links